News
Molnupiravir, an investigational oral antiviral COVID-19 treatment, receives Special Approval for Emergency in Japan.- Merck Inc., + Ridgeback Biotherapeutics.
Merck Inc., and Ridgeback Biotherapeutics announced that Japan’s Ministry of Health, Labor and Welfare has granted Special Approval for Emergency in Japan for molnupiravir, an investigational oral antiviral medicine, for infectious disease caused by SARS-CoV-2.
Special Approval for Emergency is the process under Article 14-3 of the Pharmaceuticals and Medical Devices Act to approve a medical product swiftly in an emergency situation to protect public health. Under a previously announced supply agreement, the Japanese government will purchase 1.6 million courses of molnupiravir to accelerate access to patients.
Condition: Coronavirus/COVID-19 Infection
Type: drug